Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Supernus Pharmaceuticals stock price, quote, forecast and news

SUPN
US8684591089
A1JX3U

Price

34.97
Today +/-
+0.47
Today %
+1.53 %
P

Supernus Pharmaceuticals stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Supernus Pharmaceuticals stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Supernus Pharmaceuticals stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Supernus Pharmaceuticals stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Supernus Pharmaceuticals's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Supernus Pharmaceuticals Stock Price History

DateSupernus Pharmaceuticals Price
8/23/202434.97 undefined
8/22/202434.44 undefined
8/21/202434.69 undefined
8/20/202434.43 undefined
8/19/202434.21 undefined
8/16/202434.55 undefined
8/15/202434.25 undefined
8/14/202433.27 undefined
8/13/202433.65 undefined
8/12/202432.39 undefined
8/9/202432.10 undefined
8/8/202431.48 undefined
8/7/202431.92 undefined
8/6/202427.88 undefined
8/5/202427.92 undefined
8/2/202428.78 undefined
8/1/202429.57 undefined
7/31/202429.82 undefined
7/30/202430.28 undefined
7/29/202430.59 undefined
7/26/202430.75 undefined

Supernus Pharmaceuticals Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Supernus Pharmaceuticals, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Supernus Pharmaceuticals from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Supernus Pharmaceuticals’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Supernus Pharmaceuticals. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Supernus Pharmaceuticals’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Supernus Pharmaceuticals’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Supernus Pharmaceuticals’s growth potential.

Supernus Pharmaceuticals Revenue, EBIT and net profit per share

DateSupernus Pharmaceuticals RevenueSupernus Pharmaceuticals EBITSupernus Pharmaceuticals Net Income
2029e907.8 M undefined0 undefined322.4 M undefined
2028e852.41 M undefined290.93 M undefined269.13 M undefined
2027e794.87 M undefined254.57 M undefined223.72 M undefined
2026e704.97 M undefined178.56 M undefined141.67 M undefined
2025e638.25 M undefined122.98 M undefined107.84 M undefined
2024e634.11 M undefined110.36 M undefined113.26 M undefined
2023607.52 M undefined14.92 M undefined1.32 M undefined
2022667.2 M undefined46.1 M undefined60.7 M undefined
2021579.8 M undefined108.3 M undefined53.4 M undefined
2020520.4 M undefined182.1 M undefined127 M undefined
2019392.8 M undefined148.6 M undefined113.1 M undefined
2018408.9 M undefined144.4 M undefined111 M undefined
2017302.2 M undefined99.5 M undefined57.3 M undefined
2016215 M undefined54.2 M undefined91.2 M undefined
2015147.5 M undefined20.8 M undefined13.9 M undefined
201492.7 M undefined-5.3 M undefined-10.9 M undefined
201312 M undefined-61.9 M undefined-92.3 M undefined
20121.5 M undefined-42.2 M undefined-47.4 M undefined
2011800,000 undefined-37.8 M undefined50.4 M undefined
2010100,000 undefined-40.1 M undefined-41.9 M undefined
200937.9 M undefined4 M undefined-3 M undefined
20088.9 M undefined-25.9 M undefined-36.9 M undefined
20074.2 M undefined-19 M undefined-20.7 M undefined
20066.3 M undefined-6.6 M undefined-8.2 M undefined

Supernus Pharmaceuticals Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
2006200720082009201020112012201320142015201620172018201920202021202220232024e2025e2026e2027e2028e2029e
648370011292147215302408392520579667607634638704794852907
--33.33100.00362.50---1,100.00666.6759.7846.2640.4735.10-3.9232.6511.3515.20-9.004.450.6310.3412.787.306.46
------100.0083.3393.4894.5694.4295.0396.3295.9289.8187.0586.9686.16------
00000011086139203287393376467504580523000000
-6-19-254-40-37-42-61-520549914414818210846141101221782542900
-100.00-475.00-312.5010.81---4,200.00-508.33-5.4313.6125.1232.7835.2937.7635.0018.656.902.3117.3519.1225.2831.9934.04-
-8-20-36-3-4150-47-92-1013915711111312753601113107141223269322
-150.0080.00-91.671,266.67-221.95-194.0095.74-89.13-230.00600.00-37.3694.741.8012.39-58.2713.21-98.3311,200.00-5.3131.7858.1620.6319.70
23.923.923.923.923.923.917.431.842.351.251.753.354.153.853.754.461.755.51000000
------------------------
Details

Keystats

ⓘ

Revenue and Growth

The Supernus Pharmaceuticals Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Supernus Pharmaceuticals is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (k)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (B)TOTAL ASSETS (B)LIABILITIESCOMMON STOCK (k)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (B)
2008200920102011201220132014201520162017201820192020202120222023
60.466.532.748.588.582.274.362.290.1140356347.1422.5339.7461.3254.87
2.33.40005.117.325.941.565.6102.987.3140.9148.9165.5144.16
0300200070000000000000
00001.27.213.412.616.816.325.726.648.38691.577.41
6.82.670.91.12.83.75.336.58.911.618.72715.816.68
69.572.839.949.491.597.3108.7106151.4228.4493.5472.6630.4601.6734.1493.11
21.91.21.31.42.62.43.94.35.14.138.358.152.344.142.52
000008.819.85575.4133.6418.8591.8350.4119.293.916.62
0000000000000000
1.61.41.10.90.71.25.4116.53631.424.8364.3784.7702.5599.89
00000000000077.9117.5117117.02
4.13.84.82.10.41.40.422.861.921.230.132.72313.910.98.51
0.010.010.01000.010.030.080.160.20.480.690.871.090.970.78
0.080.080.050.050.090.110.140.190.310.420.981.161.51.691.71.28
0000000010010010010010010010055
4949.149.449.4143.9212230.3264276.1295369.6388.4409.3434.3408.1439.49
-55.8-55.3-93.8-40-86.3-178.5-189.5-175.5-84.3-26.886.5199.5326.5379.9481.2482.56
0000-0.10-0.2-0.5-0.1-0.7-3.27.491.5-3.2-0.59
0000000000000000
-6.8-6.2-44.49.457.533.540.688191.8267.6453595.4744.9815.8886.2921.52
4.56.211.32.583.11.94.38.16.83.210.115.79.310.51.96
3.83.81.49.32.715.226.151.969.495.6143.6144.8189.4241.1237.5231.88
002.50.20.58.10.10.73.320.514.65.736.2653856.35
000000000000004020
0006.811.800000003.8000
8.31015.218.82326.428.156.980.8122.9161.4160.6245.1315.4688290.2
7575022.711.134.426.27.14.20329.5345.2382379.300
00000000000035.285.449.824.96
0.6176.12.82.316.741.736.632.9343459.196.993.378.541
75.67676.125.513.451.167.943.737.134363.5404.3514.1558128.365.96
83.98691.344.336.477.596100.6117.9156.9524.9564.9759.2873.4816.3356.16
0.080.080.050.050.090.110.140.190.310.420.981.161.51.691.71.28
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Supernus Pharmaceuticals provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Supernus Pharmaceuticals's financial health and stability.

Assets

Supernus Pharmaceuticals's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Supernus Pharmaceuticals must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Supernus Pharmaceuticals after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Supernus Pharmaceuticals's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
20072008200920102011201220132014201520162017201820192020202120222023
-17-330-3853-46-92-1013915711111312753601
011100000287618328584
000000000-4121-4-50-5-26-25
22040-35-1912823-40-363-22-9
0000-911297111212314345603686
06001242000122221
00000000001345145251636
-14-292-32-36-47-57-243466114129143138127116111
-100000-10-2-1-20-2-3-200
1415-282533-49-12-2-39-36-86-413-157-34-81-216268
1515-272634-48-10-2-37-34-84-412-155-31-79-216269
00000000000000000
0750030-663000030900-1370-402
000001002012577347126
064402787623012537633-130-10-397
0-1040-2-6-330000-10000-22-1
00000000000000000
050-21-724-8-73-2323391-10107-85-110-18
-15.1-29.81.9-32.8-36.9-48-59.5-25.132.465.2112.6128.2140.4135125.1116.4110.53
00000000000000000

Supernus Pharmaceuticals stock margins

The Supernus Pharmaceuticals margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Supernus Pharmaceuticals. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Supernus Pharmaceuticals.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Supernus Pharmaceuticals's sales revenue. A higher gross margin percentage indicates that the Supernus Pharmaceuticals retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Supernus Pharmaceuticals's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Supernus Pharmaceuticals's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Supernus Pharmaceuticals's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Supernus Pharmaceuticals. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Supernus Pharmaceuticals's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Supernus Pharmaceuticals Margin History

Supernus Pharmaceuticals Gross marginSupernus Pharmaceuticals Profit marginSupernus Pharmaceuticals EBIT marginSupernus Pharmaceuticals Profit margin
2029e86.21 %0 %35.51 %
2028e86.21 %34.13 %31.57 %
2027e86.21 %32.03 %28.15 %
2026e86.21 %25.33 %20.1 %
2025e86.21 %19.27 %16.9 %
2024e86.21 %17.4 %17.86 %
202386.21 %2.46 %0.22 %
202286.93 %6.91 %9.1 %
202187.05 %18.68 %9.21 %
202089.91 %34.99 %24.4 %
201995.75 %37.83 %28.79 %
201896.23 %35.31 %27.15 %
201794.97 %32.93 %18.96 %
201694.42 %25.21 %42.42 %
201594.24 %14.1 %9.42 %
201493.74 %-5.72 %-11.76 %
201390.83 %-515.83 %-769.17 %
2012100 %-2,813.33 %-3,160 %
2011100 %-4,725 %6,300 %
201086.21 %-40,100 %-41,900 %
200986.21 %10.55 %-7.92 %
200886.21 %-291.01 %-414.61 %
200786.21 %-452.38 %-492.86 %
200686.21 %-104.76 %-130.16 %

Supernus Pharmaceuticals Stock Sales Revenue, EBIT, Earnings per Share

The Supernus Pharmaceuticals earnings per share therefore indicates how much revenue Supernus Pharmaceuticals has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Supernus Pharmaceuticals earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Supernus Pharmaceuticals's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Supernus Pharmaceuticals’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Supernus Pharmaceuticals's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Supernus Pharmaceuticals Revenue, EBIT and net profit per share

DateSupernus Pharmaceuticals Sales per ShareSupernus Pharmaceuticals EBIT per shareSupernus Pharmaceuticals Earnings per Share
2029e16.51 undefined0 undefined5.87 undefined
2028e15.51 undefined0 undefined4.9 undefined
2027e14.46 undefined0 undefined4.07 undefined
2026e12.82 undefined0 undefined2.58 undefined
2025e11.61 undefined0 undefined1.96 undefined
2024e11.54 undefined0 undefined2.06 undefined
202310.94 undefined0.27 undefined0.02 undefined
202210.81 undefined0.75 undefined0.98 undefined
202110.66 undefined1.99 undefined0.98 undefined
20209.69 undefined3.39 undefined2.36 undefined
20197.3 undefined2.76 undefined2.1 undefined
20187.56 undefined2.67 undefined2.05 undefined
20175.67 undefined1.87 undefined1.08 undefined
20164.16 undefined1.05 undefined1.76 undefined
20152.88 undefined0.41 undefined0.27 undefined
20142.19 undefined-0.13 undefined-0.26 undefined
20130.38 undefined-1.95 undefined-2.9 undefined
20120.09 undefined-2.43 undefined-2.72 undefined
20110.03 undefined-1.58 undefined2.11 undefined
20100 undefined-1.68 undefined-1.75 undefined
20091.59 undefined0.17 undefined-0.13 undefined
20080.37 undefined-1.08 undefined-1.54 undefined
20070.18 undefined-0.79 undefined-0.87 undefined
20060.26 undefined-0.28 undefined-0.34 undefined

Supernus Pharmaceuticals business model

Supernus Pharmaceuticals Inc is an American company specializing in the development, manufacturing, and marketing of pharmaceuticals. The company was founded in 2005 and is headquartered in Rockville, Maryland. Initially, Supernus Pharmaceuticals focused on developing medications for neurological disorders such as epilepsy and ADHD. However, the company has since expanded into other areas of indication such as migraine and Parkinson's disease. The top products of Supernus Pharmaceuticals are the two epilepsy medications, Oxtellar XR and Trokendi XR, both based on a patented technology called "Troxerutin Enriched Osmotic Delivery System" (TREOS). This technology allows for timed release of the active ingredient, resulting in longer duration of action and improved tolerability. Both products are approved in the United States and have proven to be effective and well-tolerated. In addition to Oxtellar XR and Trokendi XR, Supernus Pharmaceuticals has launched other products on the market, including XADAGO for the treatment of Parkinson's disease and Qudexy XR for the treatment of migraine. The company also has a number of compounds in the pipeline currently in various stages of development. The business model of Supernus Pharmaceuticals is based on the development of proprietary technologies and the marketing of novel pharmaceuticals. The company works closely with industry and scientific partners to find innovative solutions to medical challenges. For Supernus Pharmaceuticals, quality is a central component of its business model. The company adheres to strict regulatory requirements and employs modern manufacturing techniques to ensure the highest standards in pharmaceutical production. Additionally, the company maintains close relationships with healthcare providers and patient organizations to ensure that its products meet the needs of patients. Supernus Pharmaceuticals also pursues a robust growth strategy based on exploring new markets and expanding its product portfolio. The company aims to expand its pipeline and develop new technologies to improve the treatment of neurological disorders and promote patient health worldwide. Overall, Supernus Pharmaceuticals is an innovative company distinguished by its commitment to quality and focus on novel solutions in the pharmaceutical industry. The company has established itself as a leading provider of medications for neurological disorders and strives to expand its position in this growing market. Supernus Pharmaceuticals is one of the most popular companies on Eulerpool.com.

Supernus Pharmaceuticals SWOT Analysis

Strengths

Supernus Pharmaceuticals Inc possesses a robust product portfolio consisting of several innovative and FDA-approved drugs. The company's diverse range of products helps it maintain a competitive edge in the pharmaceutical industry.

With years of experience operating in the pharmaceutical market, Supernus Pharmaceuticals Inc has established a strong market presence. Its reputation and brand recognition contribute to its ability to attract loyal customers and secure partnerships.

Weaknesses

Despite its success in the domestic market, Supernus Pharmaceuticals Inc has limited global reach compared to some of its competitors. Expanding into international markets presents an opportunity for the company to further grow its business.

Supernus Pharmaceuticals Inc relies heavily on a few key customers for a significant portion of its revenue. This dependency exposes the company to potential risks if any of these customers reduce or terminate their business relationships.

Opportunities

The pharmaceutical industry is seeing favorable regulatory reforms, which create opportunities for Supernus Pharmaceuticals Inc to expedite the drug approval process and bring new products to market more efficiently.

The increasing demand for specialty medications presents a growth opportunity for Supernus Pharmaceuticals Inc. By developing innovative drugs that target specific diseases or conditions, the company can tap into this growing market and expand its customer base.

Threats

Supernus Pharmaceuticals Inc operates in a highly competitive industry characterized by the presence of numerous established players. Competitors may introduce similar or superior products, potentially impacting the company's market share and profitability.

Pricing pressure and reimbursement challenges pose a threat to Supernus Pharmaceuticals Inc. The company must navigate the complex pricing and reimbursement landscape to ensure adequate compensation for its products while remaining cost-effective for patients and healthcare providers.

Supernus Pharmaceuticals Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Supernus Pharmaceuticals historical P/E ratio, EBIT, and P/S ratio.

Supernus Pharmaceuticals shares outstanding

The number of shares was Supernus Pharmaceuticals in 2023 — This indicates how many shares 55.507 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Supernus Pharmaceuticals earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Supernus Pharmaceuticals's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Supernus Pharmaceuticals’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Supernus Pharmaceuticals's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Unfortunately, there are currently no price targets and forecasts available for Supernus Pharmaceuticals.

Supernus Pharmaceuticals latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/20240.4 0.36  (-9.5 %)2024 Q2
3/31/20240.38 0.26  (-32.33 %)2024 Q1
12/31/20230.56 0.89  (57.69 %)2023 Q4
9/30/20230.08 0.24  (194.12 %)2023 Q3
6/30/20230.07 -0.02  (-130.17 %)2023 Q2
3/31/20230.17 0.29  (67.24 %)2023 Q1
12/31/20220.69 0.43  (-38 %)2022 Q4
9/30/20220.36 0.03  (-91.75 %)2022 Q3
6/30/20220.3 0.14  (-52.67 %)2022 Q2
3/31/20220.24 0.43  (75.65 %)2022 Q1
1
2
3
4
...
5

Eulerpool ESG Scorecard© for the Supernus Pharmaceuticals stock

Eulerpool World ESG Rating (EESG©)

40/ 100

🌱 Environment

43

👫 Social

41

🏛️ Governance

36

Environment

Scope 1 - Direct Emissions
—
Scope 2 - Indirect emissions from purchased energy
—
Scope 3 - Indirect emissions within the value chain
—
Total CO₂ emissions
—
CO₂ reduction strategy
✅
Coal energy
❌
Nuclear power
❌
Animal experiments
✅
Fur & Leather
—
Pesticides
—
Palm Oil
—
Tobacco
❌
Genetically modified organisms
❌
Climate concept
—
Sustainable forestry
—
Recycling regulations
❌
Environmentally friendly packaging
❌
Hazardous substances
❌
Fuel consumption and efficiency
❌
Water consumption and efficiency
❌

Social

Percentage of female employees—
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content❌
Alcohol❌
Weapons—
Firearms
❌
Gambling❌
Military contracts❌
Human rights concept❌
Privacy concept—
Occupational health and safety✅
Catholic✅

Governance (Corporate Governance)

Environmental reporting❌
Stakeholder Engagement❌
Call Back Policies❌
Antitrust law❌

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Supernus Pharmaceuticals list of shareholders

%
Name
Stocks
Change
Date
8.46 % Armistice Capital LLC4,650,000-442,00012/31/2023
4.98 % Macquarie Investment Management2,737,716-13,14012/31/2023
4.47 % Dimensional Fund Advisors, L.P.2,456,369141,58612/31/2023
3.75 % State Street Global Advisors (US)2,062,326145,31612/31/2023
3.55 % Khattar (Jack A)1,954,16734,7122/28/2024
3.53 % Polar Capital LLP1,939,365284,89512/31/2023
3.47 % Stephens Investment Management Group, LLC1,904,864200,16612/31/2023
2.98 % Loomis, Sayles & Company, L.P.1,636,490-93,77912/31/2023
2.51 % Renaissance Technologies LLC1,378,422-60,00012/31/2023
2.40 % GW&K Investment Management, LLC1,317,526-88,63212/31/2023
1
2
3
4
5
...
10

Supernus Pharmaceuticals Executives and Management Board

Mr. Jack Khattar61
Supernus Pharmaceuticals President, Chief Executive Officer, Secretary, Director (since 2005)
Compensation 10.01 M
Dr. Jonathan Rubin61
Supernus Pharmaceuticals Senior Vice President, Chief Medical Officer - Research and Development
Compensation 1.25 M
Mr. Timothy Dec65
Supernus Pharmaceuticals Chief Financial Officer, Senior Vice President
Compensation 1.25 M
Dr. Padmanabh Bhatt65
Supernus Pharmaceuticals Senior Vice President - Intellectual Property, Chief Scientific Officer
Compensation 1.12 M
Mr. Frank Mottola51
Supernus Pharmaceuticals Senior Vice President - Quality, GMP Operations and Information Technology
Compensation 1.02 M
1
2
3

Most common questions regarding Supernus Pharmaceuticals

What values and corporate philosophy does Supernus Pharmaceuticals represent?

Supernus Pharmaceuticals Inc represents values of innovation, patient-centricity, and integrity. The company is dedicated to developing and commercializing innovative therapies that address unmet medical needs. With a strong focus on neurology and psychiatry, Supernus Pharmaceuticals Inc strives to improve the lives of patients by providing effective and safe treatment options. Their corporate philosophy revolves around conducting business ethically and responsibly while maintaining transparent and collaborative relationships with healthcare professionals, patients, and stakeholders. Through their commitment to research and development, Supernus Pharmaceuticals Inc aims to make a positive impact on the healthcare industry and enhance patient well-being.

In which countries and regions is Supernus Pharmaceuticals primarily present?

Supernus Pharmaceuticals Inc is primarily present in the United States and has a strong presence in North America. With its headquarters located in Rockville, Maryland, the company has successfully expanded its operations, research, and development efforts within the region. Supernus Pharmaceuticals Inc focuses on developing and commercializing innovative therapies for various central nervous system diseases. Its dedication to improving patient's quality of life and commitment to scientific advancement has allowed the company to establish itself as a key player in the pharmaceutical industry in the US and North America.

What significant milestones has the company Supernus Pharmaceuticals achieved?

Supernus Pharmaceuticals Inc has achieved several significant milestones throughout its history. Notable achievements include the FDA approval of their flagship product, Trokendi XR, for the treatment of epilepsy and migraines. The company has also successfully launched Oxtellar XR, an antiepileptic drug, in the United States market. In addition, Supernus Pharmaceuticals Inc received FDA approval for Aptiom, an antiepileptic medication. These milestones demonstrate the company's commitment to developing innovative therapies and improving the quality of life for patients with neurological disorders. Supernus Pharmaceuticals Inc continues to focus on research and development, aiming to achieve more breakthroughs in the pharmaceutical industry.

What is the history and background of the company Supernus Pharmaceuticals?

Supernus Pharmaceuticals Inc is a pharmaceutical company specializing in the development and commercialization of innovative therapies for central nervous system diseases. Founded in 2005, Supernus has a strong history of success in bringing quality treatments to patients. Headquartered in Rockville, Maryland, the company has focused on researching and developing products for the treatment of epilepsy, attention-deficit/hyperactivity disorder (ADHD), and other neurological disorders. Supernus Pharmaceuticals Inc has established itself as a leading player in the pharmaceutical industry, delivering innovative solutions for patients and healthcare professionals. With a dedication to improving patient lives, Supernus continues to make significant contributions to the medical field through its advanced therapies.

Who are the main competitors of Supernus Pharmaceuticals in the market?

The main competitors of Supernus Pharmaceuticals Inc in the market are other pharmaceutical companies that specialize in the same therapeutic areas and products. Some of these competitors include companies like Johnson & Johnson, Pfizer Inc, Novartis AG, and Eli Lilly and Company. These companies also have a strong presence in the pharmaceutical industry and offer similar medications and treatments. However, Supernus Pharmaceuticals Inc differentiates itself through its unique product offerings and innovative research and development efforts.

In which industries is Supernus Pharmaceuticals primarily active?

Supernus Pharmaceuticals Inc is primarily active in the pharmaceutical industry.

What is the business model of Supernus Pharmaceuticals?

The business model of Supernus Pharmaceuticals Inc revolves around the development and commercialization of innovative therapies for central nervous system (CNS) diseases. Supernus specializes in creating treatments that target epilepsy, attention deficit hyperactivity disorder (ADHD), and other CNS disorders. With a focus on research and development, Supernus aims to identify novel drug candidates, conduct clinical trials, and gain regulatory approvals for its products. By combining its expertise in neuroscience and pharmaceuticals, Supernus strives to improve the lives of patients suffering from neurologic and psychiatric conditions.

What is the P/E ratio of Supernus Pharmaceuticals 2024?

The Supernus Pharmaceuticals P/E ratio is 17.14.

What is the P/S ratio of Supernus Pharmaceuticals 2024?

The Supernus Pharmaceuticals P/S ratio is 3.06.

What is the AlleAktien quality score of Supernus Pharmaceuticals?

The AlleAktien quality score for Supernus Pharmaceuticals is 3/10.

What is the revenue of Supernus Pharmaceuticals 2024?

The expected Supernus Pharmaceuticals revenue is 634.11 M USD.

How high is the profit of Supernus Pharmaceuticals 2024?

The expected Supernus Pharmaceuticals profit is 113.26 M USD.

What is the business model of Supernus Pharmaceuticals

Supernus Pharmaceuticals Inc is a leading biopharmaceutical company specializing in the development and marketing of innovative products for the treatment of central nervous system disorders. The company is headquartered in Rockville, Maryland, USA, and has offices in Canada and Europe. Supernus Pharmaceuticals Inc's business model is based on three core divisions: research and development, production, and distribution. The company aims to strengthen its research and development through strategic partnerships and acquisitions. Its product range includes a variety of drugs used to treat epilepsy, attention deficit/hyperactivity disorder (ADHD), and other drugs that affect the central nervous system. The main products of Supernus Pharmaceuticals Inc are the drugs Oxtellar XR and Trokendi XR, which are used to treat partial seizures in adults and children aged 6 and older. Oxtellar XR and Trokendi XR offer patients a once-daily dosage, increasing patient compliance and reducing the number of doses. Another important product of Supernus Pharmaceuticals Inc is Quillichew ER, used to treat ADHD in children. Quillichew ER is a once-daily chewable tablet, providing patients with a convenient way to take the medication. In addition to drug development and marketing, Supernus Pharmaceuticals Inc has also strengthened its production and distribution chain. The company owns a production facility in Montreal, Canada, and has an agreement with a company in Switzerland for drug manufacturing. The company has also entered into an agreement with a company to market Oxtellar XR, supporting sales efforts in Europe. Supernus Pharmaceuticals Inc directly distributes its products in the US and Canada. The company also has a distribution agreement with a company in Switzerland to distribute its products in Europe. In addition to drug development and marketing, Supernus Pharmaceuticals Inc operates a dedicated program to educate and support patients using its products. The company offers patient programs that provide support in medication compliance, disease management training, and access to special services and resources. Overall, Supernus Pharmaceuticals Inc has a strong business model based on the development and marketing of innovative drugs for the treatment of central nervous system disorders. The company aims to strengthen its research and development activities through strategic partnerships and acquisitions, and expand its presence internationally by strengthening its production and distribution chain. Supernus Pharmaceuticals Inc also remains committed to offering patient programs to support and care for patients using its products.

What is the Supernus Pharmaceuticals dividend?

Supernus Pharmaceuticals pays a dividend of 0 USD distributed over payouts per year.

How often does Supernus Pharmaceuticals pay dividends?

The dividend cannot currently be calculated for Supernus Pharmaceuticals or the company does not pay out a dividend.

What is the Supernus Pharmaceuticals ISIN?

The ISIN of Supernus Pharmaceuticals is US8684591089.

What is the Supernus Pharmaceuticals WKN?

The WKN of Supernus Pharmaceuticals is A1JX3U.

What is the Supernus Pharmaceuticals ticker?

The ticker of Supernus Pharmaceuticals is SUPN.

How much dividend does Supernus Pharmaceuticals pay?

Over the past 12 months, Supernus Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Supernus Pharmaceuticals is expected to pay a dividend of 0 USD.

What is the dividend yield of Supernus Pharmaceuticals?

The current dividend yield of Supernus Pharmaceuticals is .

When does Supernus Pharmaceuticals pay dividends?

Supernus Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Supernus Pharmaceuticals?

Supernus Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of Supernus Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Supernus Pharmaceuticals located?

Supernus Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von Supernus Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Supernus Pharmaceuticals from 8/24/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 8/24/2024.

When did Supernus Pharmaceuticals pay the last dividend?

The last dividend was paid out on 8/24/2024.

What was the dividend of Supernus Pharmaceuticals in the year 2023?

In the year 2023, Supernus Pharmaceuticals distributed 0 USD as dividends.

In which currency does Supernus Pharmaceuticals pay out the dividend?

The dividends of Supernus Pharmaceuticals are distributed in USD.

All fundamentals about Supernus Pharmaceuticals

Our stock analysis for Supernus Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Supernus Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.